114 results about "HIV vaccine" patented technology

The present invention includes compositions and methods for making and using a vaccine that includes a DC-specific antibody or fragment thereof to which an engineered Gag antigen is attached to form an antibody-antigen complex, wherein the Gag antigen is less susceptible to proteolytic degradation by eliminating one or more proteolytic sites or a DC-specific antibody or fragment thereof to which an engineered Nef antigen is attached to form an antibody-antigen complex, wherein the Nef antigen comprises one or more codon usage optimization that increase antibody-antigen complex secretion, or both, wherein the vaccine is able to elicit an HIV-specific T cell immune response to Gag p17, Gag p24, Nef and/or Cyclin D1.

Human immunodeficiency virus (HIV) comprising reverse transcriptase inactivated by photoinactivation used to evoke an immune response. The immune response may protect an individual from challenges with live virus. Alternatively, the inactivated HIV particles may be used to augment the immune response to HIV in an infected individual.

Human immunodeficiency virus (HIV) comprising reverse transcriptase inactivated by photoinactivation. The inactivated virus may be more safely handled, stored, and analyzed, used in diagnostic procedures and kits, and may be used as an immunogen to evoke an immune response. The immune response may protect an individual from challenges with live virus. Alternatively, the inactivated HIV particles may be used to augment the immune response to HIV in an infected individual.

The invention discloses a canine distemper attenuated vaccine strain and application thereof. In the invention, passing and cloning are performed on a separated canine distemper virulent strain to culture the canine distemper attenuated vaccine strain, and the microorganism collection number is CGMCC No.3810. The canine distemper attenuated vaccine strain of the invention can provide better protection for the canines suffering homological virulent attack, has perfect immunogenicity and can provide relatively good immune protection for the canines infected with the canine distemper virus. The attenuated vaccine strain can be prepared into single vaccine or united vaccine (live vaccine or inactivated vaccine) and can effectively prevent or cure the canine distemper. The attenuated vaccine strain of the invention has the advantages of stable transmissibility, lasting immunity, good effect, safety, reliability, long storage time and the like.

Immunogenic compositions containing a human immunodeficiency virus (HIV) gp140 protein, sorbitol, polysorbate 20, and histidine buffer are described. The described immunogenic compositions are advantageous in that they are stable at refrigerated temperature for extended periods of time, and are compatible with an adjuvant. Also described are methods of using the immunogenic compositions to induce an immune response against an HIV in a subject. The immunogenic compositions can be administered alone, or in combination with one or more additional HIV antigens, or one or more adenovirus vectors encoding the one or more additional HIV antigens.

An anti-HIV vaccine composition is disclosed. The vaccine comprises an combination of immunogenic peptide mixtures, which mixtures may be prepared in a single synthesis. The composition collectively represents the in vivo variability seen in immunogenic epitopes from highly variable regions of HIV. Immunization with the vaccine elicits broadly reactive immunity (CTL and T helper cell responses) against the divergent strains of HIV upon which it is based. The vaccine may be formulated to target regionally distinct variability based on an HIV clade predominant in a geographical region.

First generation adenoviral vectors and-recombinant adenovirus-based HIV vaccines which contain HIV-1 gag, HIV-1 pol and/or HIV-1 nef polynucleotide pharmaceutical products, and biologically relevant modifications thereof are described. The adenovirus vaccines, when directly introduced into living vertebrate tissue, express the relevant proteins, inducing a cellular immune response which specifically recognizes HIV-1. The exemplified polynucleotides of the present invention are synthetic DNA molecules encoding HIV-1 Gag, HIV-1 Pol, HIV-1 Nef, and derivatives thereof. The adenoviral vaccines of the present invention, alone or in combination, will offer a prophylactic advantage to previously uninfected individuals and/or provide a therapeutic effect by reducing viral load levels within an infected individual, thus prolonging the asymptomatic phase of HIV-1 infection.

The invention relates to the therapeutic use of a second generation immunomodulatory oligonucleotide in combination with HIV-1 antigen or immunogen to enhance the ability to reduce the risk HIV infection and to control the progression of HIV infection to prevent AIDS Related Complex (ARC) and AIDS.

Methods and compositions are provided for the use of an envelope polypeptide or a functional variant thereof from a lentivirus that is not HIV-1 as a molecular scaffold for HIV-1 epitopes. The HIV-1 epitopes can be recognized by HIV-1 binding antibodies, HIV-1 neutralizing antibodies and/or CD4-induced antibodies. Thus, methods are provided for detecting HIV-1 binding antibodies in a subject infected with HTV-1. Further provided are methods to determine an epitope for an HIV-1 binding antibody; methods to assay for an HIV-1 binding antibody; methods to identify a soluble CD4 mimic; methods to neutralize an non-HIV-1 virus; diagnostic assays to monitor HIV disease in a subject or to monitor the subject's response to immunization by a HIV vaccine; and methods to alter the neutralization potential of an HIV-1 derived CD4-induced antibody. Chimeric polypeptides, chimeric polynucleotides, kits, cells and viruses are also provided.

This invention relates to compositions and methods or the detection of immunodeficiency virus infection, especially immunodeficiency virus-1 (HIV-1) infection. The invention particularly concerns compositions and methods that may be used in HIV vaccine recipients whose sera may contain vaccine-generated anti-HIV-1 antibodies.

This invention relates to novel peptide immunogens that generate an immune response in mammals against HIV gp41, to pharmaceutical compositions that comprise such immunogens, and to methods of treating Immunodeficiency disease, especially HIV infection and AIDS, that employ such pharmaceutical compositions.

Provided herein are immunogenic compositions comprising fusion proteins, the fusion proteins comprising lentivirus gp41 or a fragment thereof, a trimerization or oligomerization motif and an immunoenhancer that elicit potent and broad HIV neutralizing antibody responses in the immunized hosts. Also disclosed are methods of making and using the immunogenic compositions.

The invention relates to a porcine parvnvirus living vaccine and a preparation method thereof. The living vaccine is prepared by adopting a PPVS-1A strain (the HA valence is not less than 29, and the TCID50 is not less than 107.0/ml) to obtain a cell culture through being inoculated with a swine testis (ST) subculture cell growing well, adding a suitable stabilizing agent and carrying out freezing vacuum drying. The virus content of each first part of the living vaccine is not less than 105.0TCID50. Compared with the prior art, the porcine parvnvirus living vaccine has good immunogenicity, rapid antibody generation after immunization, high titer and long maintenance time of the generated antibody, long retention period and small immunizing dose. When the porcine parvnvirus living vaccine is used to carry out vaccine injection a plurality of weeks before hybridization, the pregnant sow can maintain strong immunizing power in the easy infection period. The porcine parvnvirus living vaccine is the excellent choice for preventing the porcine parvnvirus. The adopted preparation method has reasonable process and lower cost and greatly reduces the cost burden of the livestock breeding.

The present invention relates to a vaccine for immunization against HIV. The vaccine has DNA sequences encoding a plurality of viral proteins, including NEF, VPU and reverse transcriptase. The vaccine is rendered nonpathogenic by the disruption of the gene(s) encoding for at least one of these proteins.

The invention discloses a preparation method for a newcastle disease and infectious bursal disease bigeminal composite inactivated vaccine and belongs to the technical field of biological products for veterinary use. The preparation method comprises preparation of a newcastle disease antigen liquid, preparation of an infectious bursal disease antigen liquid and preparation of the newcastle disease and infectious bursal disease bigeminal composite inactivated vaccine. The vaccine prepared by the invention has a dual characteristic of water in oil and oil in water and has the advantages of integration of a slow release function of the conventional vaccine and the jointed functions of a water-soluble immunopotentiator, Chinese herbal medicinal polysaccharide, an analgesic and the like. According to the preparation method, the immunity of an organism is greatly improved, and the humoral immunity is improved; the newcastle disease and infectious bursal disease bigeminal composite inactivated vaccine can stimulate the organism to generate efficient neutralizing antibodies, and the disease prevention ability of the organism is improved. According to the newcastle disease and infectious bursal disease bigeminal composite inactivated vaccine, adverse reactions of chickens caused by fractional immunization of multiple vaccines are avoided, the immunization procedure is simplified, and the investment cost is reduced. The vaccine preparation by the invention is suitable for chickens of all ages; one-day chicks are immunized, so that immunity failures of a live vaccine caused by maternal interference resistance or immunosuppression caused by high toxicity can be avoided; the newcastle disease and infectious bursal disease bigeminal composite inactivated vaccine is safely and effectively used.

A novel method for generating vaccine sequences is disclosed herein that preserves contiguous epitope length stretches of amino acids or nucleotides from an input pool of sequences. The method generates continuous, stepwise epitope consensus that together provides for a single globally optimized sequence. The end sequences are designed to maximize overlap between any potential epitope length sequence extract from a natural antigen sequence. The disclosed method, thus, allows one to maximize the number of potential natural epitopes that are mimicked in a resultant vaccine sequence. Various representative HIV vaccine sequences have been generated and are disclosed herein.

Disclosed is a method for treatment of HIV related diseases comprising targeting complexes between on the one hand the C5 domain of gpl20 and on the other hand gp41 or the C2 domain of gpl20. The complexes may be stabilised by administering compounds, such as antibodies, capable of directly interacting with and stabilising the complex, or by immunizing with C5 and gp41/C2 derived material so as to induce antibodies that bind to and stabilise the complex.